Pfizer Inc. (PFE)
Pfizer withdraws sickle cell disease treatment from all markets
U.S. drugmaker Pfizer said on Wednesday it would voluntarily withdraw its therapy Oxbryta, used for the treatment of sickle cell disease, in all markets where it is approved.
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer: Oncology Breakthroughs, GLP-1, and Strategic M&A Insights with CFO Dave Denton
In the latest episode of After Earnings, Pfizer CFO Dave Denton shares insights into the company's achievements and future strategies with Ann Berry and Katie Perry. They discuss topics like acquiring Seagen, the use of AI in drug development, and ongoing initiatives in oncology and weight management. Denton addresses shareholder concerns about financial performance, emphasizing Pfizer's dedication to innovation through significant investments in M&A and R&D. He also highlights the development of an oral GLP-1 receptor for obesity management and efforts to maintain robust dividends.
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab
The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.
Pfizer: Undervalued Healthcare Leader Poised For Further Recovery
Pfizer's transition from COVID revenue faces skepticism, as PFE underperformed its healthcare peers recently. Successful integration of Seagen is crucial for Pfizer's oncology portfolio, potentially lifting investor sentiment. Pfizer's cautious approach to weight loss drugs suggests success is far from certain, raising its execution risks to disrupt the market.
Pfizer Is Rising Past Covid-19
Pfizer Inc. (PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and antiviral therapy, establishing a household name in the process. As the pandemic faded, the stock lost over 50% of its value from its all-time high.
Here's Why Pfizer (PFE) Fell More Than Broader Market
In the closing of the recent trading day, Pfizer (PFE) stood at $29.42, denoting a -0.83% change from the preceding trading day.
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.
3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever
Now that W.P. Carey is no longer in the office-leasing business, its long-term investors can rest much easier.
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
The healthcare giant was a star stock during the height of the pandemic thanks to its vaccine. Some Pfizer investors are hungry for an encore and showing their displeasure by shunning the stock.
Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective
Pfizer (PFE) said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.
